| Market Closed –
17:37:46 03/06/2024 | After closing
| |||
| 4,228 | +2.77% | 4.21 | -0.43% | |
Valneva announced that the results of two Phase 2 clinical trials of its Lyme disease vaccine candidate, VLA15, have been published in the medical journal Lancet Infectious Diseases. The vaccine biotech specifies that these trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the ongoing pivotal Phase 3 trial, “Vaccine Against Lyme for Outdoor Recreationists” (Valor) .
“We are pleased that these results are now accessible to the entire scientific community and those working to prevent infectious diseases,” said Juan Carlos Jaramillo, medical director of Valneva. “Lyme disease is the most common vector-borne infectious disease in North America and Europe, and we are excited about ongoing trials and progress toward potentially providing a vaccine against this need. medical not satisfied.
© AOF – 2024
| Valneva: new results from the Lyme disease vaccine candidate | 18:11 | A.O. |
| Europe is rising, eyes on the ECB | 09:36 | D |
| Make us dream, Christine | 09:02 | |
| VALNEVA GAINS 1.7% AFTER RECOMMENDATION BY EMA OF ITS… | 09:00 | D |
| Direct from the Markets: Sanofi, Airbus, Thales, Atos, Casino, Tesla, Aramco, Valneva… | 08:35 |  |
| Valneva: positive opinion from the CHMP in chikungunya | 07:28 | CF |
| Values to follow in Paris and Europe (updated) | 06:00 | D |
| Valneva’s chikungunya vaccine receives support from EU regulatory committee | 31/05 | TM |
| Valneva receives positive opinion from CHMP in Europe for its chikungunya vaccine | 31/05 | DJ |
| A first vaccine against Chikungunya validated in Europe | 31/05 | A.W. |
| EU regulator recommends use of Valneva chikungunya vaccine | 31/05 | D |
| Valneva: largest increase in SBF120 at mid-session on Tuesday May 28, 2024 | 28/05 | A.O. |
| Valneva: largest increase in the SBF 120 at the close of Wednesday May 22, 2024 – | 05/22 | A.O. |
| Valneva Names Dr. Hanneke Schuitemaker, Ph.D., as Scientific Director | 05/22 | THIS |
| Valneva appoints new scientific director | 05/21 | TM |
| Valneva: Hanneke Schuitemaker appointed scientific director | 05/21 | A.O. |
| Direct from the Markets: Sanofi, Airbus, Rubis, Atos, Valneva, Microsoft, Tesla, Generali… | 05/21 | |
| Tech in orbit | 05/21 | |
| Valneva: appointment of a scientific director | 05/21 | CF |
| Valneva appoints Hanneke Schuitemaker as scientific director and member of the management board | 05/21 | DJ |
| Market point-Wait and see before Powell and an inflation indicator in the USA | 14/05 | D |
| Valneva: largest increase in the SBF 120 and SRD at mid-session on Tuesday May 14, 2024 – | 14/05 | A.O. |
| Actions on the move: Volkswagen, Valneva, Solutions 30, Delivery Hero, and many others | 14/05 | |
| Valneva announces new positive data on its chikungunya vaccine | 13/05 | DJ |
| Casino, Covivio, Sanofi: the values to follow today in Paris | 13/05 | A.O. |
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More graphics
Valneva is a specialty vaccine company that develops, manufactures and markets prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and focused approach, applying its deep expertise across multiple vaccine modalities, focusing on delivering best-in-class, best-in-class or unique vaccine solutions. Valneva has a strong track record, having advanced several vaccines from early stages of R&D through licensure, and is currently commercializing two proprietary travel vaccines as well as certain third-party vaccines leveraging its well-established commercial infrastructure. Revenues generated from its growing commercial operations contribute to the continued advancement of Valneva’s vaccine portfolio. This includes the world’s first vaccine against the chikungunya virus and the only vaccine candidate against Lyme disease in late-stage clinical development, in partnership with Pfizer, as well as vaccine candidates against the Zika virus and other threats global public health issues.
More information about the company
Purchase
Average recommendation
BUY
Last Closing Course
4,114
EUR
Average course objective
8,967
EUR
Gap / Average Objective
+117.96%
Consensus
| Varia. Jan 1 | Capi. | |
|---|---|---|
| -10.42% | 621M | |
| +46.50% | 54.63 billion | |
| -6.74% | 39.92 billion | |
| +37.07% | 38.82 billion | |
| +14.14% | 26.86 billion | |
| -11.17% | 26.22 billion | |
| -21.87% | 18.78 billion | |
| +25.87% | 12.21 billion | |
| +0.75% | 12.16 billion | |
| +26.62% | 11.94 billion |
Biotechnological and medical research – Others
